Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00763061 · ClinicalTrials.gov registry record · Phase 4
Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 111
- Enrollment target
NCT00763061 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 111 participants.
The verdict
NCT00763061, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 111 participants
- Enrollment target
Study Summary
To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.
Interventions
- DRUG Travoprost 0.004% Ophthalmic Solution (Travatan)
- DRUG Timolol 0.5% Ophthalmic Solution (Timoptic)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00763061
The ClinicalTrials.gov registry entry for NCT00763061 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Travoprost 0.004% Ophthalmic Solution (Travatan) is the first listed.
NCT00763061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00763061 about?
NCT00763061 is a clinical study titled "Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension". To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.
What is the current status of trial NCT00763061?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 111 participants. The study started on 2006-05. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00763061?
The interventions under investigation include: Travoprost 0.004% Ophthalmic Solution (Travatan) (DRUG), Timolol 0.5% Ophthalmic Solution (Timoptic) (DRUG).
Who is sponsoring clinical trial NCT00763061?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.